"Splenism" - the function of spleen, as the organ conducting the interrelation of the circulatory system and hematopoiesis
DOI:
https://doi.org/10.14739/2310-1237.2013.2.17812Keywords:
erythropoiesis, splenomegaly, hypersplenism, inhibitor of hematopoiesisAbstract
The term “hypersplenism” has long been entrenched firmly in clinical practice; it is defined as the enlargement of the spleen (splenomegaly), as a consequence of difficulties of blood outflow from the spleen, accompanied by the development of pancytopenia. Most frequently and "clean" such - secondary splenomegaly develops as a result of difficulties of blood outflow in the liver cirrhosis (in 30-50% of patients) (12). In this case, the phenomenon of hypersplenism, which manifests itself in pancytopenia, is observed in more than half of these patients (11, 18, 19, 20). However, the mechanism of anemia needs to be clarified, as a rule the emphasis is only on blood cell destruction in the congestive spleen or blood loss from the varicose veins. (14, 16, 18).Previously we (5) had found that in most of the 25 studied patients with secondary splenomegaly (cirrhosis and splenic vein thrombophlebitis) potent inhibitor of blood was detected in serum. Splenectomy led to the disappearance of the inhibitor and the activation of erythropoiesis.Materials and methods. The experiments were performed on Wistar rats, weighing 200-250 g; several models of experiments were involved. Splenomegaly was created either by ligation of splenic vein or intraperitoneal infusion of 80% saline suspension of washed red blood cells (3.5 ml/100 g body weight). In part of this group of animals spleen was tightly sheathed with capron a week before transfusion of red blood cells in order to deprive of the opportunity to deposit the excess of red blood cells. Red blood cells count, hemoglobin level and concentration of reticulocytes were studied in the dynamics. We determined the concentration of serotonin in blood and kidneys.Results and Discussion. Ligation of the splenic veins as well as deposition of the part of the transfused red blood cells in it, as evidenced by the almost two-fold increase of its mass (from 1.0-1.2 g to 2.0-2.5 g), led to the weakening of erythropoiesis. The inhibition of erythropoiesis is evidenced by the sharp decrease of the concentration of young red cells - reticulocytes and the gradual reduction of erythrocytes. Transfusion of large number of red blood cells results in the same effect.In plasma of these animals there is an active factor, which leads to inhibition of erythropoiesis. This can be concluded on the basis of the fact that the introduction of the blood serum of these animals resulted in inhibition of blood in recipients: as evidenced by the reduction in the concentration of reticulocytes. In contrast, the reproduction of erythrocytosis against the deprivation of spleen’s possibility to deposit the excess of red blood cells, in spite of the decrease in the activity of erythropoiesis, did not lead to the appearance of active inhibitor of erythropoiesis in the blood of these animals: after the introduction of serum erythropoietic activity of the recipient did not change (the concentration of reticulocytes count remained at the level of the control animals). Polyglobulia itself leads to the reduced formation of erythropoiesis stimulator - erythropoietin.Thus, we have found that enlargement of the spleen (splenomegaly), both after ligation of its veins and when depositing excess of erythrocytes in case of erythrocytosis, leads to anemia due to the formation of the active inhibitor. We believe that the active inhibitor exerts its effect through inhibition of the formation of erythropoietin in the kidney rather than by direct blocking of the bone marrow. Such inhibitor is serotonin, as its blood level increased with splenomegaly. In patients with splenomegaly source of serotonin is apparently the destruction of platelets. Increased serotonin level was found in those parts of kidneys, which are the structures that synthesize erythropoietin. Removal of the spleen leads to the significant reduction of serotonin level both in blood and kidneys.Conclusions:1. Pancytopenia develops in patients with congestive splenomegaly, it is caused not only by the destruction of blood cells, but also by active suppression of hemopoiesis.2. Serotonin is apparently the erythropoiesis depressing factor; its high concentration in the blood is detected in case of blood stagnation in the spleen.3. Hyperserotoninemia inhibits the production of erythropoietin in kidneys despite the presence of anemia. 4. Polycythemia in rats, which spleen is deprived of the possibility to deposit the blood excess, does not lead to the appearance of the inhibitor of erythropoietin.5. Spleen, performing the function of depositary, provides the connection of the circulatory system and blood formation. Taking part in deposition of excess of red blood cells in the circulatory system, spleen blocks the formation of erythropoietin, thereby reducing the formation of red blood cells. This functional mechanism of the spleen could be called "splenism". And the excessive increase of this function leads to the pathology - hypersplenism.References
Видмане-Озола И. Лапароскапическая спленэктомия у пациента с гиперспленизмом, вызванным циррозом печени. / И. Видмане-Озола, В. Бока, Е. Чунскис, С. Лейнитс, А. Ривкина, И. Калныш // Хирургия. – 2012. – №6. – С. 13–18.
Дымшиц Р.А. О гуморальной функции селезенки / Р.А. Дымшиц, Ю.П. Балдин, В.С. Зудин // Проблемы гематологии и переливания крови. – 1963. – №7. – С. 39–43.
Молдавская А.А. Морфологические критерии строения селезенки в постнатальном онтогенезе / А.А. Молдавская // Успехи совр. естествознания. – 2009. – №2. – С. 15–18.
Павлов А.Д. Эритропоэз, эритропоэтин, железо / А.Д. Павлов, Е.Ф. Моршакова, А.Г. Румянцев – М.: «ГЭОТАР-Медиа», 2011. – 300 с.
Филимонов В.И. Исследование в онтогенезе механизмов гуморальной регуляции эритропоэза и роли селезенки в этом процессе: автореф. дис. … д-ра мед. наук / В.И. Филимонов – Новосибирск, 1974.
Филимонов В.И. Эритропоэз и остеогенез. Механизм угнетения эритропоэза при репаративном процессе в костной ткани / В.И. Филимонов, Н.В. Степанова // Физиологический журнал. – 1991. – Т. 37, №2. – С. 19–24.
Филимонов В.И. Роль селезенки во взаимодействии систем кровообращения и кроветворения / В.И. Филимонов, Н.В Степанова, С.В. Цапенко // Сб. Всес. конф. Физиология висцеральных систем. – СПб., 1992. – С. 116–120.
Филимонов В.И. Патогенетическая роль серотонина в развитии анемий / В.И. Филимонов, Н.В. Степанова, И.Е. Сухомлинова // Запорожский медицинский журнал. – 2008. – №5. – С. 70–73.
Шапкин Ю.Г. Селезенка и иммунный статус организма / Ю.Г. Шапкин, В.В. Масляков // Вестник хирургии. – 2009. – №2. – С. 52–56.
Alzen G. Partial splenic embolization as an alternative to splenectomy in hypersplenism-single center experience in 16 years / Alzen G., Basedow J., Luedemann M., Berthold L.D., Zimmer K.P. // Klin. Padiatr. -2010. -Vol. 222(6). – P. 368-373.
Amin M.A. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients / Amin M.A., el-Gendy M.M., Dawoud I.E., Shoma A., Negm A.M., Amer T.A. // World J. Surg. – 2009. – Vol. 33 (8) – P. 1702–1710.
Bancu S. Spleno-renal distal and proximal shunts for hypersplenism due to hepatic cirrhosis / Bancu S., Borz C., Popescu G., Torok A., Mureşan A., Bancu L., Turcu M. // Chirurgia (Bacur). – 2007. – Vol. 102 (6). – P. 665–668.
Cesta M.F. Normal structure, function and histology of the spleen / M.F. Cesta // Toxicol Pathol. – 2006. – Vol. 34 (5). – P. 455–465.
Elira Dokekias A. Etiologic profile of hyperspleenism at the University Hospital of Brazzaville / Elira Dokekias A., Boukoumou G.A., Malanda F., Datse Y., Martin A. // Tunis Med. – 2008. – Vol. 86 (5). – P. 441–446.
Kouadio K. Splenectomy for Splenomegaly in Ivory Coast. Indications and Short Term Results / Kouadio K., Kouassi J., Ehua S., Kanga-Miessan J., Turquin T. // Mali Med. – 2006. – Vol. 21 (2). – P. 23–26.
Madhavan M. Hematological changes following early ligation of splenic artery during splenectomy in shunt surgery for portal hypertension / Madhavan M., Vimalraj V., Selvakumar E., Jyothibasu D., et al. // Trop Gastroenterol. – 2012. – Vol. 33 (1). – P. 51–54.
Mebius R. Structure and function of the spleen / R. Mebius, G. Kraal // Nature Review Imm. – 2005. – Vol. 8. – P. 606–616.
Olivera J. P. Splenomegale, hypersplenism and peripherie blood cytopaenias in patients with classical Anderson-Fabry disease / Olivera J.P., Valbuena C., Baldaia Modeira A., Fonseca E. // Virchows Arch. – 2008. – Vol. 453 (3). – P. 291–300.
Santra G. A cross-sectional study of the clinical profile and aetiological spectrum of pancytopenia in a tertiary care center / Santra G., Das B.K. // Singapore Med J. –2010. – Vol. 51 (10). – P. 806–812.
Sockrider C.S. Partial splenic embolization for hypersplenism before and after liver transplantation / Sockrider C.S., Boykin K.N., Green J., Marsala A., Mladenka M., McMillan R., Zibari G.B. // Clin Transplant. – 2002. – Vol. 16 (7). – P. 59–61.
Stepanova N.V. To the mechanism of serotonine inhibiting on erythropoietin biosynthesis / Stepanova N.V., Filimonov V.I. // European Journal of Physiology. – 1995. – V. 430, №4. – Р. 175.
Yoshida M. Portal and splenic venous thrombosis after splenectomy in patients with hypersplenism / Yoshida M., Watanabe Y., Horiuchi A., Yamamoto Y., Sugishita H., Kawachi K. // Hepatogastroendoterology. – 2009. – Vol. 56 (90). –P. 538–541.
Zhu K. Partial splenic embolization using polyvinyl alcohol particles for hypersplenism in cirrhosis: a prospective randomized study / Zhu K., Meng X., Li Z., Huang M., Guan S., Jiang Z., Shan H. // Eur J Radiol. – 2008. – Vol. 66 (1). –P. 100–106.
Деклараційний патент на корисну модель 6147, Україна, G01№33/48. Спосіб визначення серотоніну та мелатоніну в одній пробі біологічного матеріалу / Колесник Ю.М., Бєлєнічев І.Ф., Ганчева О.В., Сухомлінова І.Є. (Україна). Заявлено 11.10.2004, опубліковано 15.04.2005; Бюл. №4.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).